Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Guidance tracker
What COHANCE guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 11 Nov 2026 | Cohance Lifesciences filed the transcript of its Q2 FY27 earnings conference call held on 6 November 2026, covering results for the quarter and half year ended 30 September 2026. Management said Q2 revenue rose 13% sequentially to INR 4,767 million and adjusted EBITDA rose to INR 458 million from INR 92 million in... NSE copy | No results filed since | ||
| 07 Nov 2026 | Revised Investor Presentation for Q2 and H1 FY27, replacing the version submitted on 6 November 2026, with corrections and alignments for consistency and clarity. Q2FY27 revenue from operations was INR 4,767 Mn, down 14.2% YoY and up 12.9% QoQ; adjusted EBITDA was INR 458 Mn (9.6% margin) versus 2.2% in Q1FY27.... NSE copy | No results filed since | ||
| 06 Nov 2026 | Investor presentation on unaudited financial results for the quarter and half year ended 30 September 2026 (Q2 FY2027). Q2 FY27 consolidated revenue from operations was INR 4,766 Mn, up 12.9% QoQ but down 14.2% YoY; adjusted EBITDA was INR 459 Mn with a 9.6% margin; adjusted profit after tax was INR 74 Mn. Gross... NSE copy | No results filed since | ||
| 11 Aug 2026 | Transcript of Cohance Lifesciences' Q1 FY27 earnings conference call held on 05 August 2026, filed under Regulation 30. Management said Q1 FY27 was the company's lowest quarter ever, with consolidated revenue from operations of INR4,223 million (down 23% year-on-year) and adjusted EBITDA of INR92 million (2.2%... NSE copy | -79.5 % | -14.2 % | +2.3 % |
| 05 Aug 2026 | Cohance Lifesciences filed its investor presentation on unaudited results for the quarter ended 30 June 2026 (Q1 FY27). Q1 FY27 revenue from operations was INR 4,223 Mn, down 23.1% YoY; adjusted EBITDA was INR 92 Mn (2.2% margin) versus INR 1,341 Mn a year earlier; adjusted loss after tax was INR (430) Mn. Reported... NSE copy | -79.5 % | -14.2 % | +2.3 % |
| 15 May 2026 | Cohance Lifesciences filed the transcript of its Q4 and FY26 earnings conference call held on May 12, 2026. Himanshu Agarwal (CFO) said FY26 revenue was INR22.68 billion, down about 13% year-on-year; adjusted EBITDA was INR4.77 billion, a 21% margin; Q4 and FY26 were in line with prior guidance. Management said Q1... NSE copy | -149.3 % | -23.1 % | +2.2 % |
| 12 May 2026 | Cohance Lifesciences filed an investor presentation on its audited results for the quarter and year ended March 31, 2026. FY26 total revenue was INR 22.7 Bn, down 13.0% YoY; Adjusted EBITDA was INR 4.8 Bn (21.0% margin) and Adjusted PAT was INR 1.8 Bn (8.1% margin). Management said FY26 was a transition year... NSE copy | -149.3 % | -23.1 % | +2.2 % |
| 16 Feb 2026 | Cohance Lifesciences filed the transcript of its earnings conference call held February 12, 2026, for the quarter and nine months ended December 31, 2025. Executive Chairman Vivek Sharma said recent performance was below expectations and revised the FY26 revenue outlook to an early-to-mid double-digit decline,... NSE copy | - | - | -5.8 % |
| 12 Feb 2026 | Cohance Lifesciences filed its investor presentation on unaudited results for the quarter and nine months ended December 31, 2025. Management said FY26 is a transition and bottoming phase, and FY26 revenue guidance is revised to an early-to-mid double-digit decline; management expects a return to revenue growth in... NSE copy | - | - | -5.8 % |
| 17 Nov 2025 | Cohance Lifesciences filed the transcript of its Q2 and H1 FY26 earnings conference call held on November 12, 2025. Management said Q2 revenue was INR5,556 million, down 8% year-on-year due to deferred shipments and restocking, and up 14% adjusted for restocking; Q2 adjusted EBITDA margin was 23.2%. H1 FY26 revenue... NSE copy | -55.7 % | +77.3 % | -10.0 % |
| 12 Nov 2025 | Cohance Lifesciences filed its investor presentation on unaudited results for the quarter and half year ended September 30, 2025 (Q2FY2026 / 1HFY26). CDMO revenue declined 4% YoY in 1HFY26, mainly due to destocking in two commercial molecules, delays in some Phase 2-3 reloads and biotech funding impact at NJ Bio.... NSE copy | -55.7 % | +77.3 % | -10.0 % |
| 12 Nov 2025 | Board of Cohance Lifesciences Limited (formerly Suven Pharmaceuticals) approved unaudited standalone and consolidated Ind AS results for the quarter and half year ended September 30, 2025, at a meeting held November 12, 2025 (5:30 pm to 6:10 pm IST). Q2FY26 revenue was ₹5,556 million, down 8% year-on-year, which... NSE copy | -55.7 % | +77.3 % | -10.0 % |
| 01 Nov 2025 | Cohance Lifesciences filed the transcript of its update conference call held on October 28, 2025, on the change in directors. Executive Chairman Vivek Sharma said Managing Director Dr. Prasada Raju stepped down effective immediately, citing personal priorities, and will remain associated for an orderly transition... NSE copy | -9.9 % | +115.6 % | -8.8 % |
| 19 Aug 2025 | Cohance Lifesciences filed the transcript of its Q1 FY'26 earnings conference call (quarter ended June 30, 2025), held after the August 13, 2025 board meeting. Management said revenue grew 13% year-on-year in Q1 FY'26; excluding inventory de-stocking in Pharma CDMO, revenue growth exceeded 25%, and the Pharma CDMO... NSE copy | -9.9 % | +115.6 % | -8.8 % |
| 13 Aug 2025 | Cohance Lifesciences filed an investor presentation on its unaudited financial results for the quarter ended June 30, 2025 (Q1FY26). Management said Q1 revenue grew 13% YoY with gross margin expansion; EBITDA margins reflect planned investments in talent and business development; adjusted for inventory de-stocking,... NSE copy | -19.5 % | +138.1 % | - |
| 02 Jun 2025 | Cohance Lifesciences filed the transcript of its Q4 and FY25 earnings conference call held on May 28, 2025, following the Board meeting of the same date. Management said FY25 revenue grew 9% year-on-year to a $335 million platform, with full-year EBITDA margin of 34%; Q4 FY25 revenue grew 20% year-on-year with... NSE copy | -19.5 % | +138.1 % | - |
| 18 Feb 2025 | Suven Pharmaceuticals filed the transcript of its Q3 FY'25 and nine-month earnings conference call held February 12, 2025 (quarter and nine months ended December 31, 2024). Management said Q3 revenue grew 40% year-on-year on a pro forma combined basis, with adjusted EBITDA margin at 38.7%; nine-month revenue grew... NSE copy | -19.5 % | +138.1 % | - |
| 12 Feb 2025 | Investor presentation for Q3 and 9MFY25 (proforma basis, subject to proposed amalgamation of Cohance Lifesciences with Suven Pharmaceuticals), per management. Q3FY25 proforma revenue from operations was INR 6,764 mn, up 40% YoY; adjusted EBITDA was INR 2,620 mn (38.7% margin) and adjusted PAT was INR 1,681 mn... NSE copy | +77.3 % | +39.7 % | -2.7 % |
| 07 Dec 2024 | Suven Pharmaceuticals filed a press release and investor presentation on its acquisition of a controlling stake in NJ Bio Inc., a Princeton, US-based ADC/XDC-focused CRDMO. Suven will acquire a 56% stake at a US$100mn pre-money valuation, investing US$64.4mn in total, including US$49.4mn to buy out existing... NSE copy | +77.3 % | +39.7 % | -2.7 % |
| 17 Nov 2024 | Suven Pharmaceuticals filed the transcript of its Q2 and H1 FY25 earnings conference call held November 12, 2024 (quarter and half-year ended September 30, 2024). Management (CFO Himanshu Agarwal) said Q2 FY25 revenue rose 12% year-on-year to Rs 2.58 billion (7% excluding Sapala); adjusted EBITDA was Rs 1.11... NSE copy | +77.3 % | +39.7 % | -2.7 % |
Filings tagged as guidance, newest first (20 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 11 Nov 2026 | Legal or regulatory | Cohance Lifesciences filed the transcript of its Q2 FY27 earnings conference call held on 6 November 2026, covering results for the quarter and half year ended 30 September 2026. Management said Q2 revenue rose 13% sequentially to INR 4,767 million and adjusted EBITDA rose to INR 458 million from INR 92 million in... NSE copy |
| 06 Nov 2026 | Management change | Cohance Lifesciences filed the outcome of its board meeting held 6 November 2026, approving unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. Standalone revenue from operations for the quarter ended 30 September 2026 was Rs 416.69 crore versus Rs 497.79 crore a... NSE copy |
| 13 Aug 2026 | Credit rating | Cohance Lifesciences Limited filed intimation that CRISIL Ratings Limited, by letter dated 12 August 2026 and at the company's request, withdrew credit ratings on certain lower-limit bank facilities. CRISIL migrated ratings on the bank loan facilities of Rs 72.5 crore to 'Crisil BB/Stable/Crisil A4+ Issuer not... NSE copy |
| 11 Aug 2026 | Legal or regulatory, Management change | Transcript of Cohance Lifesciences' Q1 FY27 earnings conference call held on 05 August 2026, filed under Regulation 30. Management said Q1 FY27 was the company's lowest quarter ever, with consolidated revenue from operations of INR4,223 million (down 23% year-on-year) and adjusted EBITDA of INR92 million (2.2%... NSE copy |
| 05 Aug 2026 | Legal or regulatory | Cohance Lifesciences reported unaudited standalone and consolidated results for the quarter ended 30 June 2026, approved by the board on 5 August 2026. Consolidated revenue from operations for the quarter was Rs 422.26 crores, against Rs 549.31 crores a year earlier; consolidated net loss after tax was Rs 45.19... NSE copy |
| 20 Jul 2026 | Legal or regulatory | Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) wrote to NSE on 17 July 2026 responding to NSE's email of 10 July 2026. The NSE email sought clarification on financial results filed with the Outcome of Board Meeting dated 12 November 2025. The company said it had clarified the Non-Machine... NSE copy |
| 15 May 2026 | Management change | Cohance Lifesciences filed the transcript of its Q4 and FY26 earnings conference call held on May 12, 2026. Himanshu Agarwal (CFO) said FY26 revenue was INR22.68 billion, down about 13% year-on-year; adjusted EBITDA was INR4.77 billion, a 21% margin; Q4 and FY26 were in line with prior guidance. Management said Q1... NSE copy |
| 12 May 2026 | Legal or regulatory, Management change | Cohance Lifesciences' board, at its meeting on May 12, 2026, approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with the investor presentation and press release. Standalone revenue from operations for FY2026 was Rs 2,030.50 crore versus Rs 2,504.43... NSE copy |
| 27 Apr 2026 | Management change | Board of Cohance Lifesciences Limited, at its meeting on April 27, 2026, noted the resignation of Mr. Vivek Sharma as Executive Chairman and director, effective close of business April 30, 2026; he will continue as Special Advisor for the next 9 months. Board approved appointment of Mr. Umang Vohra (DIN: 02296740)... NSE copy |
| 16 Feb 2026 | Legal or regulatory | Cohance Lifesciences filed the transcript of its earnings conference call held February 12, 2026, for the quarter and nine months ended December 31, 2025. Executive Chairman Vivek Sharma said recent performance was below expectations and revised the FY26 revenue outlook to an early-to-mid double-digit decline,... NSE copy |
| 12 Feb 2026 | Legal or regulatory | Cohance Lifesciences Limited (formerly Suven Pharmaceuticals) filed the outcome of its board meeting held on February 12, 2026, approving unaudited standalone and consolidated Ind AS results for the quarter and nine months ended December 31, 2025. Consolidated revenue from operations for the quarter ended December... NSE copy |
| 03 Dec 2025 | Credit rating | Cohance Lifesciences Limited (formerly Suven Pharmaceuticals) filed a Regulation 30 disclosure dated December 3, 2025 on a credit rating. India Ratings & Research assigned a rating of IND AA/Stable/IND A1+ to the Company's bank loan facilities, size of issue INR 6,850 million, rating action "Assigned". The annexure... NSE copy |
| 01 Nov 2025 | Legal or regulatory, Management change | Cohance Lifesciences filed the transcript of its update conference call held on October 28, 2025, on the change in directors. Executive Chairman Vivek Sharma said Managing Director Dr. Prasada Raju stepped down effective immediately, citing personal priorities, and will remain associated for an orderly transition... NSE copy |
| 27 Aug 2025 | Credit rating | CRISIL upgraded the long-term bank loan facilities rating of Cohance Lifesciences Limited to 'CRISIL AA-/Positive' from 'CRISIL A+', removing it from 'Rating Watch with Positive Implications'; the short-term rating of 'CRISIL A1+' was reaffirmed. Total bank loan facilities rated are Rs 72.5 crore, per the rating... NSE copy |
| 19 Aug 2025 | Management change | Cohance Lifesciences filed the transcript of its Q1 FY'26 earnings conference call (quarter ended June 30, 2025), held after the August 13, 2025 board meeting. Management said revenue grew 13% year-on-year in Q1 FY'26; excluding inventory de-stocking in Pharma CDMO, revenue growth exceeded 25%, and the Pharma CDMO... NSE copy |
| 13 Aug 2025 | Management change | Cohance Lifesciences filed an investor presentation on its unaudited financial results for the quarter ended June 30, 2025 (Q1FY26). Management said Q1 revenue grew 13% YoY with gross margin expansion; EBITDA margins reflect planned investments in talent and business development; adjusted for inventory de-stocking,... NSE copy |
| 13 Aug 2025 | Legal or regulatory | Cohance Lifesciences (formerly Suven Pharmaceuticals) filed its board meeting outcome on August 13, 2025, approving unaudited standalone and consolidated Ind AS results for the quarter ended June 30, 2025. Standalone revenue from operations for the quarter ended June 30, 2025 was Rs 483.5 crore (as printed... NSE copy |
| 29 May 2025 | Legal or regulatory, Credit rating | CRISIL has continued its long-term bank facility rating of Cohance Lifesciences Limited at CRISIL A+/Watch Positive (Rating Watch with Positive Implications) and reaffirmed the short-term rating at CRISIL A1+, covering bank loan facilities of Rs.72.5 crore. The watch was placed on Feb 29, 2024, after the announced... NSE copy |
| 28 May 2025 | Legal or regulatory | Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) filed its investor presentation and press release on audited results for the quarter and year ended March 31, 2025. The Ministry of Corporate Affairs approved the name change from Suven Pharmaceuticals Limited to Cohance Lifesciences Limited,... NSE copy |
| 28 Feb 2025 | Credit rating | Suven Pharmaceuticals Limited filed a credit rating disclosure under Regulation 30, dated February 28, 2025, citing a CRISIL letter received the same day. CRISIL continued the long-term bank facilities rating at CRISIL A+/Watch Positive (Rating Watch with Positive Implications) and reaffirmed the short-term rating... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (25 in all). A list of what was filed, not a judgement of the company.